Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib followed by sunitinib vs sunitinib followed by sorafenib in first-line advanced/metastatic renal cell carcinoma
2008-005011-18Phase 3Completed
- Sponsor
- Deutsche Krebsgesellschaft
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sorafenib and sunitinib in renal cell carcinoma (RCC) (2 arms), sponsored by Deutsche Krebsgesellschaft. Primary endpoint: total Progression Free Survival. Started Aug 2008; status: completed.
02
Drugs
sorafenibsunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2008-005011-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005011-18.